The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial

Details

• Alternative Title:
  BMC Infect Dis
• Personal Author:
  Meloni, Seema T. ; Agbaji, Oche ; Chang, Charlotte A. ; Agaba, Patricia ; Imade, Godwin ; Oguche, Stephen ; Mukhtar, Ahmed ; Mitruka, Kiren ; Cox, Mackenzie Hurlston ; Zee, Aaron ; Kanki, Phyllis
• Description:
  Background
  
  The Joint United Nations Programme on HIV/AIDS 90–90-90 goal envisions 90% of all people receiving antiretroviral therapy to be virally suppressed by 2020. Implied in that goal is that viral load be quantified for all patients receiving treatment, which is a challenging undertaking given the complexity and high cost of standard-of-care viral load testing methods. Recently developed point-of-care viral load testing devices offer new promise to improve access to viral load testing by bringing the test closer to the patient and also returning results faster, often same-day. While manufactures have evaluated point-of-care assays using reference panels, empiric data examining the impact of the new technology against standard-of-care monitoring in low- and middle-income settings are lacking. Our goal in this trial is to compare a point-of-care to standard-of-care viral load test on impact on various clinical outcomes as well to assess the acceptability and feasibility of using the assay in a resource-limited setting.
  
  Methods
  
  Using a two-arm randomized control trial design, we will enroll 794 patients from two different HIV treatment sites in Nigeria. Patients will be randomized 1:1 for point-of-care or standard-of-care viral load monitoring (397 patients per arm). Following initiation of treatment, viral load will be monitored at patients’ 6- and 12-month follow-up visits using either point-of-care or standard-of-care testing methods, based on trial assignment. The monitoring schedule will follow national treatment guidelines. The primary outcome measure in this trial is proportion of patients with viral suppression at month 12 post-initiation of treatment. The secondary outcome measures encompass acceptability, feasibility, and virologic impact variables.
  
  Discussion
  
  This clinical trial will provide information on the impact of using point-of-care versus standard-of-care viral load testing on patient clinical outcomes; the study will also supply data on the acceptability and feasibility of point-of-care viral load monitoring in a resource-limited setting. If this method of testing is acceptable and feasible, and also superior to standard of care, the results of the trial and the information gathered will inform future scaled implementation and further optimization of the clinic-laboratory network that is critical for monitoring achievement of the 90–90-90 goals.
  
  Trial registration
  
  US National Institutes of Health Clinical Trials.gov: NCT03533868. Date of Registration: 23 May 2018. Protocol Version: 10. Protocol Date: 30 March 2018.
  
  
• Subjects:
  Adolescent Adult Anti-Retroviral Agents Child HIV Infections Humans Point-of-Care Systems Viral Load
• Source:
  BMC Infect Dis. 19
• Pubmed ID:
  31046695
• Pubmed Central ID:
  PMC6495593
• Document Type:
  Journal Article
• Funding:
  D43 TW007995/TW/FIC NIH HHS/United States ; U01 GH002109/GH/CGH CDC HHS/United States ; U01GH002109/ACL HHS/United States ; U01GH002109/Center for Global Health/
• Place as Subject:
  Nigeria
• Location:
  Africa
• Volume:
  19
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:646c43a2c531f0ab370b0d16357abc5b20f462f093ca86c49ffc4c9ae2df495f
• Download URL:
  https://stacks.cdc.gov/view/cdc/81493/cdc_81493_DS1.pdf
• File Type:
  [PDF - 1.13 MB ]